加载中
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
前收盘价
US$1.03
−US$0.05 · -4.63%
盘中时间采用ET。市场数据可能有所延迟。
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
日内区间
当前US$1.03
52周区间
当前US$1.03
盘中时间采用ET。市场数据可能有所延迟。
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
日内区间
当前US$1.03
52周区间
当前US$1.03
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 713.7万 USD | 2096.8万 USD | 4186.7万 USD | 2302.8万 USD |
| 销货成本 | 9.5万 USD | 81.2万 USD | 643.3万 USD | 751.4万 USD | 155.4万 USD |
| 毛利 | −9.5万 USD | 632.5万 USD | 1453.5万 USD | 3435.3万 USD | 2147.4万 USD |
| 研究与开发 | 1801.1万 USD | 3275.5万 USD | 1.08亿 USD | 9175.9万 USD | 8257.8万 USD |
| 销售、一般及管理费用 | 873.7万 USD | 2638.8万 USD | 2764.9万 USD | 3012.9万 USD | 2797.9万 USD |
| 营业费用 | 2674.8万 USD | 6210.6万 USD | 1.36亿 USD | 1.22亿 USD | 1.11亿 USD |
| 利息收入 | 137.5万 USD | 282.8万 USD | 131.8万 USD | 65.4万 USD | 60.3万 USD |
| 利息支出 | — | 847.3万 USD | — | 3000 USD | — |
| 折旧和摊销 | 9.5万 USD | 19.2万 USD | 25.9万 USD | 8.5万 USD | 155.4万 USD |
| 营业利润 | −2674.8万 USD | −5578.1万 USD | −1.21亿 USD | −8753.5万 USD | −8908.3万 USD |
| 净利润 | −1821.4万 USD | −7086.7万 USD | −1.19亿 USD | −8547.4万 USD | −8844.1万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$8.75
上涨空间 749.51%评级样本有限，仅4项
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2025年4月16日 | 1:3 | — | — |
股票拆分 | 2024年12月31日 | 1:12 | — | — |
已生效 2025年4月16日
1:3
已生效 2024年12月31日
1:12
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
